Leukocyte adhesion deficiency (LAD) is an autosomal recessive disorder characterized by impaired migration of cells of the innate immune system, primarily neutrophils, from the intravascular space. 1 This migratory defect stems from impaired adhesion of marginated neutrophils to the vascular endothelium, thereby pre-empting neutrophil diapedesis and localized antimicrobial activity. Normally, stable neutrophil adhesion is mediated by interactions between b2 leukocyte integrins (CD11/CD18) and counter ligands of the intercellular adhesion molecule family inducibly expressed on endothelial cell surfaces at inflammatory foci. 2 Leukocyte adhesion deficiency syndromes stem from dysfunction of neutrophil migration. Three forms of LAD have been described.
3 LAD1, the predominant form, stems from absent or severely impaired CD18 expression, preventing the stable leukocyte-endothelial engagement necessary for neutrophil egress from microvasculature. Severe LAD, regardless of the molecular defect, results in frequent and potentially fatal infections. The treatment of LAD has been problematic. Although intense antibiotic therapy and granulocyte transfusion are used during acute infectious episodes, children with LAD frequently die from infectious sequelae during the first 5 years of life. 4 Although retrovirus-mediated gene therapy has been attempted, the only curative treatment for LAD is allogeneic stem cell transplant (SCT). Pre-clinical data suggest that donor chimerism of only 5% may be sufficient to protect patients with LAD from recurrent pyogenic infections post transplant. [5] [6] [7] [8] As such, strategies that maximize the probability of engraftment and donor tolerance while minimizing toxicity may be particularly efficacious in definitive LAD treatment.
The patient is a 20-year-old male, diagnosed shortly after birth with LAD, following delayed umbilical cord scission and concurrent omphalitis with Pseudomonas sepsis. Early disease manifestations included recurrent sinopulmonary infections and persistent skin ulcerations of the extremities, groin, scrotum and perirectal areas. Aggressive supportive care measures included surgical debridement, maggot instillation and split thickness skin grafting. The patient was regularly hospitalized for serious bacterial infections, and on several occasions required donor leukocyte infusions. An attempt at definitive therapy was made using retrovirus-mediated CD18 gene replacement, which ultimately was unsuccessful. The patient was referred for SCT as a means of potential cure for LAD1. Pre-transplant evaluation was significant for dental disease and a 4 cm ulcerated lesion in the groin. A reduced-intensity transplant was planned and approved by the Institutional Review Board at Vanderbilt University.
The preparative regimen consisted of fludarabine, 30 mg/m 2 , administered intravenously on 6 consecutive days (days À8 to À3), busulfan, 4 mg/kg, administered orally on 2 consecutive days (days À6 and À5) and lowdose total body irradiation of 200 cGy per day for 2 consecutive days (days À2 and À1). Bone marrow from an HLA-matched (allelic match at HLA A,B,C, DR and DQ) unrelated donor was infused on day 0. Total nucleated and CD34 þ cell dose infused was 2.5 Â 10 8 /kg and 4.1 Â 10 6 /kg, respectively. The patient received cyclosporine (CSA) and mycophenylate mofetil (MMF) for GVHD prophylaxis. Cyclosporine levels were monitored as troughs and dosage adjusted to maintain a target serum concentration of 400-450 ng/ml initially and 250-350 ng/ml subsequently.
Blood for flow cytometry was obtained 2 weeks pretransplant and monthly beginning 3 weeks post transplant. Leukocytes were immunostained with anti-human CD18 antibody (MHM23; Dakocytomation) to detect donorderived leukocytes. Leukocytes were co-stained with anti-CD13 (WM-47; Dakocytomation) to differentiate myeloid from lymphoid cells. Side scatter was used to differentiate myeloid populations (high side scatter) from lymphoid populations (low side scatter). 7-Amino actinomycin-D was used to gate non-viable cells. Leukocytes were analyzed on a Becton Dickinson FACScan and using FlowJo software (Treestar Software). Before transplantation, few myeloid cells (high SSC or CD13 þ ) were CD18 þ , consistent with LAD1. The few neutrophils present are likely residual cells left from a recent granulocyte infusion, used to treat an active infection. The small percentage of CD18 þ lymphocytes (3%) (low SSC, CD13À) have been present in the patient for several years and likely represent lymphocytes in which the CD18 gene has undergone a reversion to wild type or obtained a compensatory mutation that allows CD18 expression (T. Bauer, unpublished). The patient achieved neutrophil engraftment (ANC4500) on day þ 13, and platelet engraftment (420 000 for 7 consecutive days) on day þ 17. Peripheral blood leukocyte examination by fluorescence in situ hybridization directed at sex chromosomes revealed 99% donor chimerism on day þ 18 (data not shown). At 3 weeks post transplant, nearly all leukocytes were of donor origin as indicated by the large percentage of CD18 þ cells in the myeloid and lymphoid populations, with less than 5% of the cells remaining as CD18À (Figure 1a ). This high level of donor CD18 þ leukocytes was present at 1 year follow-up post transplant. Cutaneous ulcerative lesions present at the time of transplant, and reflective of the underlying diagnosis of LAD1, resolved after engraftment (Figure 1b) . His posttransplant course was complicated by grade 2 acute GVHD and extensive skin chronic GVHD. He also developed a significant aerodigestive Candida infection resistant to all commercially available anti-fungal therapy. The patient died 16 months post transplant after developing pneumonia. He declined aggressive therapy including bronchoscopy, and chose to receive palliative care.
This represents the first report of an unrelated bone marrow transplant following a reduced-intensity conditioning regimen in an adult patient with LAD. This report is particularly informative because previous descriptions of SCT in LAD have demonstrated that conventional myeloablative conditioning regimens are frequently not sufficient to result in complete donor chimerism. 5, 6 Furthermore, our patient engrafted readily despite extensive antecedent therapy, including multiple donor leukocyte infusions. There have been three reported cases of URD transplant for LAD employing full preparative regimens with busulfan, cyclophosphamide7etoposide. 5 Of these patients, one failed to engraft and required a second transplant. A more recent report demonstrated sustained engraftment in three children with LAD receiving reducedintensity conditioning with alemtuzumab, fludarabine and melphalan. 9 Although our patient engrafted promptly, he developed multiple treatment-resistant infections, likely reflecting his lifelong exposure to multiple antibacterial and antifungal therapies. Our findings demonstrate that this reduced-intensity regimen can achieve rapid and sustained donor engraftment despite exposure to multiple leukocyte transfusions. Ideally, patients with LAD should be referred for transplant at a young age, before developing multiple resistant infections. 
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